Mohammed H Elkomy
Overview
Explore the profile of Mohammed H Elkomy including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
49
Citations
495
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Elkomy M, Hendawy O, Zaki R, Tulbah A, Aldosari B, Ali A, et al.
Drug Deliv Transl Res
. 2024 Dec;
PMID: 39666261
Tizanidine HCl (TZN) is an FDA-approved medication for treating spasticity. However, its oral administration presents obstacles to its efficacy, as it has a short duration of action and a low...
2.
Alsaidan O, Elkomy M, Zaki R, Tulbah A, Yusif R, Eid H
J Pharm Sci
. 2024 Aug;
113(11):3304-3314.
PMID: 39216538
The current research aimed to design and optimize hyaluronic acid-coated transbilosomes containing venlafaxine (VLF-HA-TBLs) for nose-to-brain delivery for improved management of depressive disorder. Venlafaxine-loaded transbilosomes (VLF-TBLs) were developed according to...
3.
El Menshawe S, Shalaby K, Elkomy M, Aboud H, Ahmed Y, Abdelmeged A, et al.
Int J Pharm X
. 2024 Jan;
7:100225.
PMID: 38230407
Celecoxib (CLX), a selective inhibitor for cyclooxygenase 2 (COX-2), has manifested potential activity against diverse types of cancer. However, low bioavailability and cardiovascular side effects remain the major challenges that...
4.
Tulbah A, Elkomy M, Zaki R, Eid H, Eissa E, Ali A, et al.
Int J Pharm X
. 2023 Aug;
6:100206.
PMID: 37637477
This work aimed to develop and produce lacosamide-loaded niosomes coated with chitosan (LCA-CTS-NSM) using a thin-film hydration method and the Box-Behnken design. The effect of three independent factors (Span 60...
5.
Elkomy M, Abo El-Ela F, Zaki R, Alsaidan O, Elmowafy M, Zafar A, et al.
Pharmaceutics
. 2023 Aug;
15(8).
PMID: 37631309
Depression is a serious mental disorder and the most prevalent cause of disability and suicide worldwide. Quercetin (QER) demonstrated antidepressant effects in rats exhibiting anxiety and depressive-like behaviors. In an...
6.
Elkomy M, Zaki R, Alsaidan O, Elmowafy M, Zafar A, Shalaby K, et al.
Pharmaceutics
. 2023 Jul;
15(7).
PMID: 37513991
Numerous neurological disorders have a pathophysiology that involves an increase in free radical production in the brain. Quercetin (QER) is a nutraceutical compound that shields the brain against oxidative stress-induced...
7.
Elmowafy M, Shalaby K, Elkomy M, Alsaidan O, Gomaa H, Hendawy O, et al.
Drug Deliv Transl Res
. 2023 Mar;
13(10):2568-2588.
PMID: 37000409
Growing evidence suggests quercetin and aspirin may have anticancer properties, notably in the case of colorectal cancer. The goal of this study was to create Pluronic F127 and polyethylene glycol4000...
8.
Elhabal S, Ghaffar S, Hager R, Elzohairy N, Khalifa M, Mohie P, et al.
Int J Pharm X
. 2023 Mar;
5:100174.
PMID: 36908304
The most prevalent conditions among ocular surgery and COVID-19 patients are fungal eye infections, which may cause inflammation and dry eye, and may cause ocular morbidity. Amphotericin-B eye drops are...
9.
Elmowafy M, Shalaby K, Elkomy M, Alsaidan O, Gomaa H, Abdelgawad M, et al.
Polymers (Basel)
. 2023 Mar;
15(5).
PMID: 36904364
In the last few decades, several natural bioactive agents have been widely utilized in the treatment and prevention of many diseases owing to their unique and versatile therapeutic effects, including...
10.
Elmowafy M, Shalaby K, Elkomy M, Alsaidan O, Gomaa H, Abdelgawad M, et al.
Int J Pharm
. 2023 Mar;
635:122782.
PMID: 36858890
No abstract available.